Journal of Hepatology
Volume 54, Issue 1 , Pages 48-55 , January 2011

Small molecule scavenger receptor BI antagonists are potent HCV entry inhibitors

  • Andrew J. Syder

      Affiliations

    • iTherX Pharmaceuticals, Inc., P.O. Box 910530, San Diego, CA 92191-0530, USA
    • ,
  • Haekyung Lee

      Affiliations

    • iTherX Pharmaceuticals, Inc., P.O. Box 910530, San Diego, CA 92191-0530, USA
    • ,
  • Mirjam B. Zeisel

      Affiliations

    • Inserm, U748, Université de Strasbourg, F-67000 Strasbourg, France
    • ,
  • Joe Grove

      Affiliations

    • Institute for Biomedical Research, University of Birmingham, Vincent Drive, Birmingham B15 2TT, UK
    • ,
  • Eric Soulier

      Affiliations

    • Inserm, U748, Université de Strasbourg, F-67000 Strasbourg, France
    • ,
  • James Macdonald

      Affiliations

    • iTherX Pharmaceuticals, Inc., P.O. Box 910530, San Diego, CA 92191-0530, USA
    • ,
  • Stephine Chow

      Affiliations

    • iTherX Pharmaceuticals, Inc., P.O. Box 910530, San Diego, CA 92191-0530, USA
    • ,
  • Julia Chang

      Affiliations

    • iTherX Pharmaceuticals, Inc., P.O. Box 910530, San Diego, CA 92191-0530, USA
    • ,
  • Thomas F. Baumert

      Affiliations

    • Inserm, U748, Université de Strasbourg, F-67000 Strasbourg, France
    • Pôle Hépato-digestif, Hôpitaux Universitaires de Strasbourg, F-67000 Strasbourg, France
    • ,
  • Jane A. McKeating

      Affiliations

    • Institute for Biomedical Research, University of Birmingham, Vincent Drive, Birmingham B15 2TT, UK
    • ,
  • Jeffrey McKelvy

      Affiliations

    • iTherX Pharmaceuticals, Inc., P.O. Box 910530, San Diego, CA 92191-0530, USA
    • ,
  • Flossie Wong-Staal

      Affiliations

    • iTherX Pharmaceuticals, Inc., P.O. Box 910530, San Diego, CA 92191-0530, USA
    • Corresponding Author InformationCorresponding author. Tel.: +1 858 824 1114; fax: +1 858 824 1112.

Received 7 April 2010 ,Revised 10 June 2010 ,Accepted 14 June 2010.

References 

  1. Shepard CW, Finelli L, Alter MJ. Global epidemiology of hepatitis C virus infection. Lancet Infect Dis. 2005;5:558–567
  2. Takaki A, Wiese M, Maertens G, Depla E, Seifert U, Liebetrau A, et al. Cellular immune responses persist and humoral responses decrease two decades after recovery from a single-source outbreak of hepatitis C. Nat Med. 2000;6:578–582
  3. Seeff LB, Hoofnagle JH. National institutes of health consensus development conference: management of hepatitis C: 2002. Hepatology. 2002;36:S1–S2
  4. Davis GL, Alter MJ, El-Serag H, Poynard T, Jennings LW. Aging of the hepatitis C virus (HCV)-infected persons in the United States: a multiple cohort model of HCV prevalence and disease progression. Gastroenterology. 2010;138:513–521
  5. Grunberger C, Wyles DL, Kaihara KA, Schooley RT. 3-Drug synergistic interactions of small molecular inhibitors of hepatitis C virus replication. J Infect Dis. 2008;197:42–45
  6. Thompson AJ, McHutchison JG. Antiviral resistance and specifically targeted therapy for HCV (STAT-C). J Viral Hepat. 2009;16:377–387
  7. Dorr P, Westby M, Dobbs S, Griffin P, Irvine B, Macartney M, et al. Maraviroc (UK-427, 857), a potent, orally bioavailable, and selective small-molecule inhibitor of chemokine receptor CCR5 with broad-spectrum anti-human immunodeficiency virus type 1 activity. Antimicrob Agents Chemother. 2005;49:4721–4732
  8. Zeisel MB, Barth H, Schuster C, Baumert TF. Hepatitis C virus entry: molecular mechanisms and targets for antiviral therapy. Front Biosci. 2009;14:3274–3285
  9. Pileri P, Uematsu Y, Campagnoli S, Galli G, Falugi F, Petracca R, et al. Binding of hepatitis C virus to CD81. Science. 1998;282:938–941
  10. Evans MJ, von Hahn T, Tscherne DM, Syder AJ, Panis M, Wolk B, et al. Claudin-1 is a hepatitis C virus co-receptor required for a late step in entry. Nature. 2007;446:801–805
  11. Liu S, Yang W, Shen L, Turner JR, Coyne CB, Wang T. Tight junction proteins claudin-1 and occludin control hepatitis C virus entry and are downregulated during infection to prevent superinfection. J Virol. 2009;83:2011–2014
  12. Ploss A, Evans MJ, Gaysinskaya VA, Panis M, You H, de Jong YP, et al. Human occludin is a hepatitis C virus entry factor required for infection of mouse cells. Nature. 2009;457:882–886
  13. Scarselli E, Ansuini H, Cerino R, Roccasecca RM, Acali S, Filocamo G, et al. The human scavenger receptor class B type I is a novel candidate receptor for the hepatitis C virus. EMBO J. 2002;21:5017–5025
  14. Acton S, Rigotti A, Landschulz KT, Xu S, Hobbs HH, Krieger M. Identification of scavenger receptor SR-BI as a high density lipoprotein receptor. Science. 1996;271:518–520
  15. Rigotti A, Miettinen HE, Krieger M. The role of the high-density lipoprotein receptor SR-BI in the lipid metabolism of endocrine and other tissues. Endocr Rev. 2003;24:357–387
  16. Callens N, Ciczora Y, Bartosch B, Vu-Dac N, Cosset FL, Pawlotsky JM, et al. Basic residues in hypervariable region 1 of hepatitis C virus envelope glycoprotein e2 contribute to virus entry. J Virol. 2005;79:15331–15341
  17. Dreux M, Boson B, Ricard-Blum S, Molle J, Lavillette D, Bartosch B, et al. The exchangeable apolipoprotein ApoC-I promotes membrane fusion of hepatitis C virus. J Biol Chem. 2007;282:32357–32369
  18. Bartosch B, Verney G, Dreux M, Donot P, Morice Y, Penin F, et al. An interplay between hypervariable region 1 of the hepatitis C virus E2 glycoprotein, the scavenger receptor BI, and high-density lipoprotein promotes both enhancement of infection and protection against neutralizing antibodies. J Virol. 2005;79:8217–8229
  19. Barth H, Schnober EK, Neumann-Haefelin C, Thumann C, Zeisel MB, Diepolder HM, et al. Scavenger receptor class B is required for hepatitis C virus uptake and cross-presentation by human dendritic cells. J Virol. 2008;82:3466–3479
  20. Voisset C, Callens N, Blanchard E, Op De Beeck A, Dubuisson J, Vu-Dac N. High density lipoproteins facilitate hepatitis C virus entry through the scavenger receptor class B type I. J Biol Chem. 2005;280:7793–7799
  21. von Hahn T, Lindenbach BD, Boullier A, Quehenberger O, Paulson M, Rice CM, et al. Oxidized low-density lipoprotein inhibits hepatitis C virus cell entry in human hepatoma cells. Hepatology. 2006;43:932–942
  22. Zeisel MB, Koutsoudakis G, Schnober EK, Haberstroh A, Blum HE, Cosset FL, et al. Scavenger receptor class B type I is a key host factor for hepatitis C virus infection required for an entry step closely linked to CD81. Hepatology. 2007;46:1722–1731
  23. Catanese MT, Graziani R, von Hahn T, Moreau M, Huby T, Paonessa G, et al. High-avidity monoclonal antibodies against the human scavenger class B type I receptor efficiently block hepatitis C virus infection in the presence of high-density lipoprotein. J Virol. 2007;81:8063–8071
  24. Grove J, Huby T, Stamataki Z, Vanwolleghem T, Meuleman P, Farquhar M, et al. Scavenger receptor BI and BII expression levels modulate hepatitis C virus infectivity. J Virol. 2007;81:3162–3169
  25. Bartosch B, Vitelli A, Granier C, Goujon C, Dubuisson J, Pascale S, et al. Cell entry of hepatitis C virus requires a set of co-receptors that include the CD81 tetraspanin and the SR-B1 scavenger receptor. J Biol Chem. 2003;278:41624–41630
  26. Kapadia SB, Barth H, Baumert T, McKeating JA, Chisari FV. Initiation of hepatitis C virus infection is dependent on cholesterol and cooperativity between CD81 and scavenger receptor B type I. J Virol. 2007;81:374–383
  27. Lavillette D, Tarr AW, Voisset C, Donot P, Bartosch B, Bain C, et al. Characterization of host-range and cell entry properties of the major genotypes and subtypes of hepatitis C virus. Hepatology. 2005;41:265–274
  28. Masson D, Koseki M, Ishibashi M, Larson CJ, Miller SG, King BD, et al. Increased HDL cholesterol and apoA-I in humans and mice treated with a novel SR-BI inhibitor. Arterioscler Thromb Vasc Biol. 2009;29:2054–2060
  29. Zhong J, Gastaminza P, Cheng G, Kapadia S, Kato T, Burton DR, et al. Robust hepatitis C virus infection in vitro. Proc Natl Acad Sci USA. 2005;102:9294–9299
  30. Krieger SE, Zeisel MB, Davis C, Thumann C, Harris HJ, Schnober EK, et al. Inhibition of hepatitis C virus infection by anti-claudin-1 antibodies is mediated by neutralization of E2-CD81-Claudin-1 associations. Hepatology. 2009;51:1144–1157
  31. Yang JP, Zhou D, Wong-Staal F. Screening of small-molecule compounds as inhibitors of HCV entry. Methods Mol Biol. 2009;510:295–304
  32. Haberstroh A, Schnober EK, Zeisel MB, Carolla P, Barth H, Blum HE, et al. Neutralizing host responses in hepatitis C virus infection target viral entry at postbinding steps and membrane fusion. Gastroenterology. 2008;135:1719–1728e1711
  33. Gu X, Kozarsky K, Krieger M. Scavenger receptor class B Type I-mediated [3H]cholesterol efflux to high and low density lipoproteins is dependent on lipoprotein binding to the receptor. J Biol Chem. 2000;275:29993–30001
  34. Acton SL, Scherer PE, Lodish HF, Krieger M. Expression cloning of SR-BI A CD36-related class B scavenger receptor. J Biol Chem. 1994;269:21003–21009
  35. Grove J, Nielsen S, Zhong J, Bassendine MF, Drummer HE, Balfe P, et al. Identification of a residue in hepatitis C virus E2 glycoprotein that determines scavenger receptor BI and CD81 receptor dependency and sensitivity to neutralizing antibodies. J Virol. 2008;82:12020–12029
  36. Zhong J, Gastaminza P, Chung J, Stamataki Z, Isogawa M, Cheng G, et al. Persistent hepatitis C virus infection in vitro: coevolution of virus and host. J Virol. 2006;80:11082–11093
  37. Sabahi A. Hepatitis C Virus entry: the early steps in the viral replication cycle. Virol J. 2009;6:117
  38. McKelvy J, Lee H, Syder AJ, Chang J, MacDonald J, Wong-Staal F. ITX 5061, an orally bioavailable, clinical stage compound, targets scavenger receptor BI to inhibit HCV entry [Abstract]. In: 16th international symposium on hepatitis C virus & related viruses; 2009. p.85 (O-61).
  39. Dreux M, Dao Thi VL, Fresquet J, Guerin M, Julia Z, Verney G, et al. PLoS Pathog. 2009;5:e1000310
  40. Catanese MT, Ansuini H, Graziani R, Huby T, Moreau M, Ball JK, et al. Role of scavenger receptor class B type I in hepatitis C virus entry: kinetics and molecular determinants. J Virol. 2010;84:34–43
  41. Drummer HE, Poumbourios P. Hepatitis C virus glycoprotein E2 contains a membrane-proximal heptad repeat sequence that is essential for E1E2 glycoprotein heterodimerization and viral entry. J Biol Chem. 2004;279:30066–30072
  42. Ikonen E. Cellular cholesterol trafficking and compartmentalization. Nat Rev Mol Cell Biol. 2008;9:125–138
  43. Yalaoui S, Huby T, Franetich JF, Gego A, Rametti A, Moreau M, et al. Scavenger receptor BI boosts hepatocyte permissiveness to plasmodium infection. Cell Host Microbe. 2008;4:283–292
  44. Rocha-Perugini V, Lavie M, Delgrange D, Canton J, Pillez A, Potel J, et al. BMC Microbiol. 2009;9:111
  45. Ashraf MZ, Kar NS, Chen X, Choi J, Salomon RG, Febbraio M, et al. Specific oxidized phospholipids inhibit scavenger receptor bi-mediated selective uptake of cholesteryl esters. J Biol Chem. 2008;283:10408–10414
  46. Zeisel MB, Cosset FL, Baumert TF. Host neutralizing responses and pathogenesis of hepatitis C virus infection. Hepatology. 2008;48:299–307
  47. Timpe JM, Stamataki Z, Jennings A, Hu K, Farquhar MJ, Harris HJ, et al. Hepatitis C virus cell–cell transmission in hepatoma cells in the presence of neutralizing antibodies. Hepatology. 2008;47:17–24
  48. Pestka JM, Zeisel MB, Blaser E, Schurmann P, Bartosch B, Cosset FL, et al. Rapid induction of virus-neutralizing antibodies and viral clearance in a single-source outbreak of hepatitis C. Proc Natl Acad Sci USA. 2007;104:6025–6030
  49. Osburn WO, Fisher BE, Dowd KA, Urban G, Liu L, Ray SC, et al. Spontaneous control of primary hepatitis C virus infection and immunity against persistent reinfection. Gastroenterology. 2010;138:315–324
  50. Wright TL, Donegan E, Hsu HH, Ferrell L, Lake JR, Kim M, et al. Recurrent and acquired hepatitis C viral infection in liver transplant recipients. Gastroenterology. 1992;103:317–322

PII: S0168-8278(10)00714-2

doi: 10.1016/j.jhep.2010.06.024

Journal of Hepatology
Volume 54, Issue 1 , Pages 48-55 , January 2011

Article Tools

* Image Usage & Resolution